【24h】

Letter to the Editor

机译:给编辑的信

获取原文
获取原文并翻译 | 示例
           

摘要

With great interest we read the paper by Kang et al on the analgesic effects of keta-mine infusion therapy in Korean patients with neuropathic pain.Since 1994, various articles based on case reports, pilot studies, and clinical trials have documented the value and tolerability of ketamine for the treatment of neuropathic pain states.Due to its unique mechanism of action, ketamine is a highly interesting drug for treatment-resistant neuropathic pain syndromes, administered via various routes. Long periods of decreased pain can be triggered by relatively short courses of infusion. Dutch anesthesiologists found that complex regional pain syndrome type 1 (CRPS-1) patients with severe pain treated for 4 days with a continuous infusion of low-dose S-ketamine (N = 30) had a clinically relevant and statistically significant reduction in pain lasting for up to 11 weeks compared with patients receiving placebo (P < 0.001). However, one of the troublesome clinical aspects of treatment using intravenous ketamine is the reemergence of pain after some weeks and, therefore, the necessity to readminister treatment.
机译:我们非常有兴趣地阅读了Kang等人的论文,探讨了Keta-mine输注疗法对韩国神经性疼痛患者的镇痛作用.1994年以来,基于病例报告,先导研究和临床试验的各种文章已证明其价值和耐受性由于其独特的作用机制,氯胺酮是治疗耐药性神经性疼痛综合征的一种非常有趣的药物,可通过多种途径给药。相对较短的输注过程可引起长时间的疼痛减轻。荷兰麻醉学家发现,连续输注低剂量S-氯胺酮(N = 30)治疗4天的重度疼痛的1型复杂局部疼痛综合征(CRPS-1)患者在临床上具有统计学意义,并且统计学上显着减轻了疼痛与接受安慰剂的患者相比,治疗时间长达11周(P <0.001)。然而,使用静脉内氯胺酮治疗的麻烦临床方面之一是几周后疼痛再次出现,因此有必要重新进行治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号